Drug development through the formal clinical trials process is slow and expensive. Real World Evidence (RWE) drug development is fast and cheap. Have we got your attention yet?

The Democratic leader of a key U.S. Senate committee on Monday released the text of legislation that, if enacted, would finally allow Washington, D.C. to legalize recreational marijuana sales—in contravention of the wishes of President Joe Biden.

The “crippling labor shortages” plaguing the U.S. economy are directly attributable to the Mental Health Crisis. Psychedelic medicine is the only answer.

The fight to end the criminalization of psychedelics and give patients access to natural plants and fungi has achieved success in a growing number of cities and states in recent years, and on Thursday the cause got a boost from prominent people in the entertainment and political fields.

The U.S. Department of Agriculture’s National Agricultural Statistics Service (NASS) plans to send 20,500 hemp producers across the country their first Hemp Acreage and Production Survey, beginning October 18.

Novamind’s new DEA licenses open up opportunities to host formal clinical trials.

MindMed joins the Clinical Trials Transformation Initiative, a forward-looking healthcare association that develops/promotes new health therapies.

PharmaTher receives its second FDA orphan drug designation for a ketamine-based therapy.

Cybin files a new patent application in support of the development of drug candidate CYB004.

Denver activists, police officials and other experts have agreed upon a set of recommendations to expand the city’s historic vote to decriminalize psilocybin in 2019—including by deprioritizing criminal enforcement against additional activities like gifting and communal use of the fungi.